Chronic migraine is a disabling condition that affects hundreds of millions of individuals worldwide. The development of novel migraine treatments has been slow, in part as a result of a lack of predicative animal models. We have developed a new model of chronic migraine involving the use of nitroglycerin (NTG), a known migraine trigger in humans. Chronic intermittent administration of NTG to mice resulted in acute mechanical hyperalgesia with each exposure as well as a progressive and sustained basal hyperalgesia. This chronic basal hyperalgesia occurred in a dose-dependent fashion and persisted for days after cessation of NTG administration. NTG-evoked hyperalgesia was exacerbated by the phosphodiesterase 5 inhibitor sildenafil, also a human migraine trigger, consistent with nitric oxide as a primary mediator of this hyperalgesia. The acute but not the chronic basal hyperalgesia was significantly reduced by the acute migraine therapy sumatriptan, whereas both the acute and chronic hyperalgesia was significantly attenuated by the migraine preventive therapy topiramate. Chronic NTG-induced hyperalgesia is a mouse model that may be useful for the study of mechanisms underlying progression of migraine from an episodic to a chronic disorder, and for the identification and characterization of novel acute and preventive migraine therapies. Ó
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Introduction
Migraine is one of the most common disorders affecting the general population, resulting in a staggering amount of episodic disability and lost productivity worldwide. For a significant percentage of patients, it results in chronic disability [4, 28, 29, 32] . Despite the extraordinarily high prevalence of migraine, our understanding of its pathophysiology is incomplete. Moreover, although there has been significant progress in the acute treatment of migraine attacks, the ability to treat frequent and chronically disabling migraine remains severely limited. There continue to be millions of individuals for whom currently available migraine therapies are either ineffective or poorly tolerated [4, 29] .
A significant obstacle to the identification of new migraine therapies has been the lack of predictive animal models. There are a number of promising models for acute migraine attack [2,3,12,25], but it has been particularly difficult to study the progression of migraine from an episodic to a chronic disorder. One approach to modeling acute migraine is the quantification of increased sensory sensitivity in response to known migraine triggers. Nitroglycerin (NTG) reliably triggers headache in normal subjects, and it triggers migraine without aura in migraine-susceptible patients [1,9,17,24]. NTG-evoked migraine is a commonly used experimental paradigm in humans (for review, see [15, 24, 23] ). NTG-evoked hyperalgesia in rodents has been developed as a model for sensory hypersensitivity associated with migraine [3, 20] . Acute NTG was previously shown to produce thermal and mechanical allodynia in mice that was reversed by the antimigraine therapy sumatriptan [3] . In addition, in a transgenic mouse model of familial migraine, animals expressing a human migraine gene showed an even greater sensitivity to NTG-evoked hyperalgesia [6] . Further, NTG has also been shown to produce light-aversive behavior [20] and increased meningeal blood flow in mice [13, 20] . Taken together, these results indicate that the effects of NTG may effectively model migrainelike symptoms in rodents. Here we have extended the NTG-evoked hypersensitivity assays to model the progression of migraine from an acute to a chronic state.
